![]() | ![]() |
GlycoNex Signs Manufacturing Deal with Sterling for GNX102-ADC Clinical Trial Production
GNX102-ADC combines GlycoNex's proprietary monoclonal antibody (mAb), GNX102, and cytotoxic drug therapies to elicit cellular cytotoxicity to target cancer cells with high specificity.
Sterling Pharma Solutions | 13/11/2024 | By Aishwarya | 125
Sterling Pharma Solutions acquires Novartis' API manufacturing facility in Ireland
The 111-acre site, located near Cork, includes multiple commercial-scale production buildings, with a total vessel capacity of 175 cubic meters across over 30 reactor trains
Sterling Pharma Solutions | 11/01/2023 | By Sudeep Soparkar | 642
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy